TCT conference to reveal stent market trends

By Lisa Kerner

Charlotte, N.C., Oct. 23 - The 18th Annual Transcatheter Cardiovascular Therapeutics Scientific Symposium (TCT 2006) Oct. 22 to 27 is expected to focus on stenting, particularly drug-eluting stent (DES) safety, according to a report from RBC Capital Markets analyst Phil Nalbone.

Big-cap cardiology players and physicians are expected to attempt to put into perspective late stent thrombosis, a thorn in the side of the $5.2 billion worldwide DES market as two dominant players in the market, Johnson & Johnson and Boston Scientific, face the challenge of increased competition.

At the Washington, D.C., conference, Boston Scientific will try to bolster its Taxus franchise and defuse late stent thrombosis worries. According to Nalbone, a successful Promus launch early next year will "cannibalize" sales of Taxus.

Look for increased share gains in the DES market from Abbott and its "rising star" Xience platform in Europe and Medtronic Inc.'s Endeavor featuring a clean safety profile.

Key presentations include Abbott's results of its 3,500-patient carotid study (Capture), its Prospect study and its bioabsorbable stent trial (Absorb).

While there won't be any new breakthrough clinical data at TCT, there will be plenty of presentations, symposia and workshops covering drug-eluting stents.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.